hVIVO Regulatory News (HVO)

For immediate release 07.00: 19 March 2014

RETROSCREEN VIROLOGY GROUP PLC

("Retroscreen" or the "Company")

NEW STATE OF THE ART BIOMEDICAL FACILITY IN UK

Retroscreen Virology Group plc (AIM: RVG), the viral challenge and "virometrics" specialist, is pleased to announce that it has signed a long term lease on a facility at the Chesterford Research Park in the UK with the plan to create a state of the art biomedical facility. This new bespoke facility will allow the further development and commercial exploitation of the Company's viral challenge technology platform.

Located at Little Chesterford in North Essex, the 42,000 square foot facility will house a quarantine unit, containing 40 ensuite isolation beds, together with a separate suite of laboratories for the Company's bioanalytical work. The facility, which is targeted to be fully operational in early 2015, will dramatically improve and broaden the Company's operational capability. In particular, this planned expansion will allow the Company both to conduct clinical studies for its clients and to leverage its new viral challenge models for commercial and research purposes.

Kym Denny, Chief Executive Officer, commented, "Retroscreen is actively broadening its capabilities and this new bespoke facility at Chesterford will allow us to undertake bedside to bench biomedical research all on one site. This exciting development follows the successful inoculation of our 1,500th volunteer which was achieved in just over a year since reaching the landmark of our 1,000th volunteer inoculation on 10 December 2012. This is a testament to the industry's adoption of our viral challenge models and our client delivery."

For further information please contact:

Retroscreen Virology Group plc +44 207 756 1300

Kym Denny (CEO)

Graham Yeatman (FD)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)